Natalia Maximovsky, NP
Adult Health · Staten Island, NYNPI 1265990097
Payments from drug & device makers
Across 104 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$491
- Aucta Pharmaceuticals, Inc.$285
- Scilex Pharmaceuticals Inc.$214
- Otsuka America Pharmaceutical, Inc.$212
- Pfizer$139
- Novartis$85
- plus $475 from 18 others
What the payments were for
- Food & beverage$1,900100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 31 | $491 |
| Aucta Pharmaceuticals, Inc. | 16 | $285 |
| Scilex Pharmaceuticals Inc. | 9 | $214 |
| Otsuka America Pharmaceutical, Inc. | 9 | $212 |
| Pfizer | 8 | $139 |
| Novartis | 5 | $85 |
| Nestle Healthcare Nutrition Inc. | 4 | $78 |
| Exact Sciences | 3 | $62 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Advanced Oxygen Therapy Inc. | 2 | $29 |
| Ardelyx, Inc. | 1 | $28 |
| Shield Therapeutics Inc | 1 | $24 |
| AstraZeneca | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Vivus LLC | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Avion Pharmaceuticals | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
| Amgen | 1 | $11 |
How this compares
$1,900 in reported general payments places this provider in the 80th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 916 | $632,964 |
| LinzessLinaclotide | 657 | $368,764 |
| ZenpepLipase/Protease/Amylase | 264 | $305,782 |
| Diclofenac Sodium | 1,090 | $303,558 |
| CreonLipase/Protease/Amylase | 222 | $249,271 |
| JanuviaSitagliptin Phosphate | 232 | $156,273 |
| OzempicSemaglutide | 150 | $136,659 |
| VascepaIcosapent Ethyl | 343 | $127,760 |
| XareltoRivaroxaban | 142 | $104,072 |
| ProcritEpoetin Alfa | 34 | $86,573 |
| Budesonide ErBudesonide | 21 | $78,219 |
| TradjentaLinagliptin | 132 | $77,651 |
| EntrestoSacubitril/Valsartan | 98 | $76,579 |
| RexultiBrexpiprazole | 52 | $73,940 |
| NamzaricMemantine Hcl/Donepezil Hcl | 87 | $69,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Namzaric, Ubrelvy | $491 | $712,166984 claims |
| PfizerEliquis | $139 | $632,964916 claims |
| Aimmune Therapeutics, Inc.Zenpep | $20 | $305,782264 claims |
| Johnson & JohnsonXarelto, Procrit | $16 | $190,645176 claims |
| NovartisEntresto | $85 | $76,57998 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $212 | $73,94052 claims |
| AstraZenecaFarxiga | $22 | $21,32439 claims |
| Sanofi-aventis U.S. LLCMultaq | $18 | $18,94525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,828 adult health providers in New York.
Other adult health in Staten Island
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Mary CiechoskiBuffalo$200K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.